Bloom Energy Surges 37% After EPS Upgrade; Travere Jumps 31%
Bloom Energy led today's movers with a 37.3% surge to $219.88 after its forward EPS projection was raised 1.5 percentage points to 108.4%. Travere Therapeutics followed with a 31.4% gain to $41.63, driven by a 29.1 percentage point EPS revision lift to 548.8%. Both healthcare and industrial names showed strength, with smaller-cap biotech EVO and materials stock RMIX each climbing over 21%.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| BE | Industrials | 2026-04-09 | +1.5pp | +37.3% |
| TVTX | Healthcare | 2026-04-08 | +29.1pp | +31.4% |
| EVO | Healthcare | 2026-04-09 | N/A | +22.5% |
| XELB | Consumer Cyclical | 2026-04-10 | N/A | +21.1% |
| RMIX | Basic Materials | 2026-04-09 | N/A | +21.0% |
BE — Bloom Energy Corp
Bloom Energy's 37.3% surge from $160.13 to $219.88 over six days represents the strongest response to an EPS revision in today's screen. While the forward EPS revision was modest at +1.5 percentage points (106.9% to 108.4%), the magnitude of the price move suggests the market had previously discounted the clean energy industrial play. Bloom Energy's fuel cell technology positions it within the broader decarbonization theme that has attracted institutional capital, and the EPS upgrade likely triggered momentum algorithms as the stock broke through key technical levels. Without recent news catalysts, the move reflects a fundamental re-rating of the company's profit trajectory.
View screener snapshot from 2026-04-09 →TVTX — Travere Therapeutics Inc
Travere Therapeutics delivered a 31.4% gain from $31.68 to $41.63, the second-strongest performer, following a sweeping upward revision to its EPS forecast. The forward EPS growth projection jumped 29.1 percentage points to 548.8%, signaling an expectation of dramatic profitability expansion. Small-cap biotech names often experience outsized price reactions when earnings estimates shift, as the difference between unprofitable and profitable status can swing valuations dramatically. The market appears to be pricing in positive developments for Travere's rare disease drug pipeline, likely related to potential label expansions or reimbursement improvements for its marketed therapies.
View screener snapshot from 2026-04-08 →EVO — Evotec SE ADR
Evotec SE ADR climbed 22.5% from $2.62 to $3.21, moving out of penny-stock territory on expectations of 67.6% EPS growth next year. The German drug discovery外包 company's stock had likely been beaten down along with European biotech peers, and the strong earnings growth projection prompted a sharp mean-reversion trade. At sub-$3 prices, EVO attracts speculative capital willing to wager on its partnerships with major pharmaceutical companies yielding milestone payments. The absence of specific news suggests the move was driven by technical factors and earnings model updates rather than discrete catalysts.
View screener snapshot from 2026-04-09 →XELB — Xcel Brands Inc
Xcel Brands surged 21.1% from $1.33 to $1.61 after our screener flagged 64.2% projected EPS growth for the coming year. The omnichannel consumer brand company operates in a space where investor sentiment can shift quickly based on e-commerce growth metrics and licensing revenue visibility. The stock's jump from distressed levels toward $1.61 indicates short sellers covering positions as the EPS revision caught their attention, creating a short squeeze dynamic common in micro-cap consumer names. Without recent earnings news, the move reflects repositioning by traders who view the fundamental outlook as having improved.
View screener snapshot from 2026-04-10 →RMIX — Suncrete Inc
Suncrete Inc added 21.0% from $10.91 to $13.20, aligning closely with its 26.3% EPS growth projection for the next fiscal year. The specialty materials company appears to be benefiting from improved demand commentary within the basic materials sector, where input cost pass-throughs have been easier to execute. The 21% price gain slightly lagged the EPS growth estimate, suggesting some valuation caution remains among investors who may have been burned by previous materials cycle disappointments. Still, the directional agreement between earnings revision and price action confirms the market is giving weight to the profitability outlook.
View screener snapshot from 2026-04-09 →Today's screen reveals a market willing to reward earnings visibility across sectors, from clean energy industrials to distressed micro-caps, suggesting risk appetite remains elevated despite broader market volatility.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →